(CercleFinance.com) – On the occasion of its activity update, the biotechnology company Innate Pharma posted a turnover for the first nine months of 2022 of 44.3 million euros, compared to 10.3 million over the same period in 2021.
For the nine-month period ended at the end of September 2022, revenue comes mainly from collaboration and license agreements with AstraZeneca and Sanofi, corresponding to the accounting spread over the period of payments received in this context.
The laboratory specializing in immuno-oncology claims cash, cash equivalents and financial assets of 151.4 million euros as of September 30, with an expected horizon during the second half of 2024.